BR9815348A - " composto, uso deste ou de um sal farmacologicamente aceitável, éster ou outro derivado do mesmo, medicamento, agentes preventivos ou terapêuticos para asma e/ou bronquite, para rinite, para doença alérgica, e para incontinência urinária, e, processos de prevenção ou tratamento de asma e/ou bronquite, de rinite, de doença alérgica, e de incontinência urinária. " - Google Patents

" composto, uso deste ou de um sal farmacologicamente aceitável, éster ou outro derivado do mesmo, medicamento, agentes preventivos ou terapêuticos para asma e/ou bronquite, para rinite, para doença alérgica, e para incontinência urinária, e, processos de prevenção ou tratamento de asma e/ou bronquite, de rinite, de doença alérgica, e de incontinência urinária. "

Info

Publication number
BR9815348A
BR9815348A BR9815348-0A BR9815348A BR9815348A BR 9815348 A BR9815348 A BR 9815348A BR 9815348 A BR9815348 A BR 9815348A BR 9815348 A BR9815348 A BR 9815348A
Authority
BR
Brazil
Prior art keywords
optionally substituted
urinary
procedure
bronchitis
rhinitis
Prior art date
Application number
BR9815348-0A
Other languages
English (en)
Inventor
Takahide Nishi
Takeshi Yamaguchi
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of BR9815348A publication Critical patent/BR9815348A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

"COMPOSTO, USO DESTE OU DE UM SAL FARMACOLOGICAMENTE ACEITáVEL, éSTER OU OUTRO DERIVADO DO MESMO, MEDICAMENTO, AGENTES PREVENTIVOS OU TERAPêUTICOS PARA ASMA E/OU BRONQUITE, PARA RINITE, PARA DOENçA ALéRGICA, E PARA INCONTINêNCIA URINáRIA, E, PROCESSOS DE PREVENçãO OU TRATAMENTO DE ASMA E/OU BRONQUITE, DE RINITE, DE DOENçA ALéRGICA, E DE INCONTINêNCIA URINáRIA" [Objeto] Prover compostos tendo atividade antagonística seletiva contra receptor NK~ 2~. [Meio para resolver o objeto] Um composto de fórmula (I), um sal farmaceuticamente aceitável ou derivado do mesmo: {R¹: cicloalquila opcionalmente substituída, ou grupo heterocíclico opcionalmente substituído; R² arila opcionalmente substituída, ou heteroarila opcionalmente substituída; A: metileno, carbonila ou sulfonila; B: ligação única, alquileno ou alquenileno; D: átomo de oxigênio ou átomo de enxofre; G: alquileno ou alquenileno; L - -N(R³)- ou -C(R^ 4^)(R^ 5^)-, [R³: arila opcionalmente substituída ou heteroarila opcionalmente substituída; R^ 4^: H, arila opcionalmente substituída, heteroarila opcionalmente substituída, cicloalquila opcionalmente substituída ou grupo heterocíclico saturado opcionalmente substituído; R^ 5^ alquila opcionalmente substituída com amino, amino, acilamino opcionalmente substituído, OH, hidroxialquila opcionalmente substituída, alcoxi ou -CO-R^ 6^ (R^ 6^: alquila, alcoxi ou resíduo amina); ou R^ 4^ junto com R^ 5^ : anel cicloalcano, anel cicloalqueno, anel heterocíclico saturado]; R^ 7^: alquila; Z: dois átomos de hidrogênio ou um átomo de oxigênio; n: 0, 1 ou 2}.
BR9815348-0A 1997-12-04 1998-12-04 " composto, uso deste ou de um sal farmacologicamente aceitável, éster ou outro derivado do mesmo, medicamento, agentes preventivos ou terapêuticos para asma e/ou bronquite, para rinite, para doença alérgica, e para incontinência urinária, e, processos de prevenção ou tratamento de asma e/ou bronquite, de rinite, de doença alérgica, e de incontinência urinária. " BR9815348A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP33460897 1997-12-04
PCT/JP1998/005500 WO1999028307A1 (fr) 1997-12-04 1998-12-04 Derives heterocycliques alicycliques acyles

Publications (1)

Publication Number Publication Date
BR9815348A true BR9815348A (pt) 2000-10-17

Family

ID=18279291

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9815348-0A BR9815348A (pt) 1997-12-04 1998-12-04 " composto, uso deste ou de um sal farmacologicamente aceitável, éster ou outro derivado do mesmo, medicamento, agentes preventivos ou terapêuticos para asma e/ou bronquite, para rinite, para doença alérgica, e para incontinência urinária, e, processos de prevenção ou tratamento de asma e/ou bronquite, de rinite, de doença alérgica, e de incontinência urinária. "

Country Status (19)

Country Link
US (1) US6288059B1 (pt)
EP (1) EP1048658B1 (pt)
KR (1) KR100610538B1 (pt)
CN (1) CN1121398C (pt)
AT (1) ATE297906T1 (pt)
AU (1) AU734908B2 (pt)
BR (1) BR9815348A (pt)
CA (1) CA2312770A1 (pt)
DE (1) DE69830615T2 (pt)
ES (1) ES2243012T3 (pt)
HK (1) HK1031870A1 (pt)
HU (1) HUP0004321A3 (pt)
IL (1) IL136510A (pt)
NO (1) NO318794B1 (pt)
NZ (1) NZ504848A (pt)
PL (1) PL341013A1 (pt)
PT (1) PT1048658E (pt)
TR (1) TR200001622T2 (pt)
WO (1) WO1999028307A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2791346B3 (fr) 1999-03-25 2001-04-27 Sanofi Sa Nouveaux derives de morpholine, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2796069B3 (fr) 1999-07-09 2001-08-24 Sanofi Synthelabo Nouveaux procedes de preparation de derives de 2-(2- arylmorpholin-2-yl)ethanol substitues, enantiomeriquement purs, et composes intermediaires utiles dans ces procedes
FR2824828B1 (fr) * 2001-05-21 2005-05-20 Sanofi Synthelabo Nouveaux derives de piperidinecarboxamide, un procede pour leur preparation et les compositions pharmaceutiques les contenant
CA2489255A1 (en) * 2002-06-11 2003-12-18 Sankyo Company Limited Process for producing cyclic thioether and synthetic intermediate thereof
US7396930B2 (en) 2002-06-11 2008-07-08 Sankyo Company, Limited Process for producing cyclic thioether and synthetic intermediate thereof
JP2004067673A (ja) * 2002-06-11 2004-03-04 Sankyo Co Ltd 環状チオエーテル類の製造法及びその合成中間体
FR2873373B1 (fr) * 2004-07-23 2006-09-08 Sanofi Synthelabo Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856962A (en) * 1973-07-10 1974-12-24 R Alphin Anti-inflammatory agents
AU607735B2 (en) * 1987-05-07 1991-03-14 A.H. Robins Company, Incorporated Novel cyclic carbamate derivatives
DE3723797A1 (de) * 1987-07-18 1989-01-26 Merck Patent Gmbh Oxazolidinone
US5086055A (en) * 1990-12-24 1992-02-04 A. H. Robins Company, Incorporated Series of 5-[-(4-aryl-1-piperazinyl)alkyl]-2-oxazolidinone derivatives useful in the treatment of allergic conditions
AU2223495A (en) * 1994-04-15 1995-11-10 Yamanouchi Pharmaceutical Co., Ltd. Spiro compound and medicinal composition thereof
TW432061B (en) * 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams
FR2729954B1 (fr) * 1995-01-30 1997-08-01 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
HU224225B1 (hu) * 1995-12-01 2005-06-28 Sankyo Co. Ltd. Tachikinin receptor antagonista hatású heterociklusos vegyületek, ezek előállítási eljárása és alkalmazásuk gyógyszerkészítmények előállítására
GB9600235D0 (en) * 1996-01-05 1996-03-06 Pfizer Ltd Therapeutic agents
GB9601202D0 (en) * 1996-01-22 1996-03-20 Pfizer Ltd Piperidones
JP3192631B2 (ja) * 1997-05-28 2001-07-30 三共株式会社 飽和複素環化合物からなる医薬

Also Published As

Publication number Publication date
NO20002833D0 (no) 2000-06-02
KR20010032721A (ko) 2001-04-25
IL136510A (en) 2005-09-25
WO1999028307A1 (fr) 1999-06-10
ES2243012T3 (es) 2005-11-16
PT1048658E (pt) 2005-10-31
EP1048658B1 (en) 2005-06-15
PL341013A1 (en) 2001-03-12
HUP0004321A3 (en) 2002-04-29
DE69830615T2 (de) 2006-03-16
EP1048658A1 (en) 2000-11-02
HUP0004321A2 (hu) 2002-02-28
ATE297906T1 (de) 2005-07-15
EP1048658A4 (en) 2002-11-05
RU2000114184A (ru) 2004-02-20
CN1121398C (zh) 2003-09-17
DE69830615D1 (de) 2005-07-21
IL136510A0 (en) 2001-06-14
CA2312770A1 (en) 1999-06-10
CN1284070A (zh) 2001-02-14
AU734908B2 (en) 2001-06-28
US6288059B1 (en) 2001-09-11
NO20002833L (no) 2000-08-03
NO318794B1 (no) 2005-05-09
KR100610538B1 (ko) 2006-08-09
AU1352399A (en) 1999-06-16
TR200001622T2 (tr) 2001-07-23
NZ504848A (en) 2002-10-25
HK1031870A1 (en) 2001-06-29

Similar Documents

Publication Publication Date Title
WO2000066614A8 (en) 3α-HYDROXY-3β METHOXYMETHYL-21-HETEROCYCLE SUBSTITUTED STEROIDS WITH ANESTHETIC ACTIVITY
GEP19991870B (en) Alkyl Amine Derivatives of Substituted Quinoxaline 2,3-Diones as Glutamate Receptor Antagonists
BR9907040A (pt) Composto, composição farmacêutica, e, processos para tratar ou prevenir condições causadas pela adesão de células mediada por alfa4 em um paciente e para preparar o composto
KR970701174A (ko) 신규한 카바메이트 유도체 및 이의 의약 조성물(Novel carbamate derivative and medicinal composition containing the same)
EP1548008A4 (en) COMPOUND HAVING BETA-TRANSFORMING GROWTH FACTOR INHIBITORY ACTIVITY AND DRUG CONTAINING COMPOSITION
BR9806413A (pt) Composto e uso do mesmo
FI950309A0 (fi) Proliiniamidijohdannaisia
ES2141174T3 (es) 4-arilmetiloximetil piperidinas como antagonistas de taquiquinina.
BRPI0509307A (pt) compostos de alfa aril ou heteroaril metil beta piperidino propanamida como antagonistas do receptor orl1
BR9913903A (pt) Composto, método para tratar ou impedir um estado doentio, e, composição farmacêutica
BR0211305A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças ou condições e uso de um composto
BR9807132A (pt) Derivados de pirrolidina tendo atividade inibitória de fosfolipase a2
ATE173256T1 (de) Azolidindion-derivate und ihre anwendung als antihyperglykämika
ATE318799T1 (de) Pyrrolderivate und medizinische zubereitung.
BR0006333A (pt) Compostos heteroaril-fenil-pirazol como agentesantiinflamatórios e analgésicos
BR0213464A (pt) Derivados de 3-azabiciclo[3.1.0]hexano como antagonistas receptores de opióide
EP1243268A4 (en) MEDICINAL COMPOSITION
ES2123546T3 (es) Uso de derivados de 1-(aminoalquil)-3-quinoxalina-2-ona para la preparacion de composiciones neuroprotectoras.
BR9815348A (pt) " composto, uso deste ou de um sal farmacologicamente aceitável, éster ou outro derivado do mesmo, medicamento, agentes preventivos ou terapêuticos para asma e/ou bronquite, para rinite, para doença alérgica, e para incontinência urinária, e, processos de prevenção ou tratamento de asma e/ou bronquite, de rinite, de doença alérgica, e de incontinência urinária. "
BR0110211A (pt) Derivados de oxadiazol tendo efeitos anticâncer
WO1996005166A1 (fr) Derive d'amine substitue et composition medicamenteuse le contenant
CA2302943A1 (en) Phthalazine compounds and therapeutic agents for erectile dysfunction
BR9907173A (pt) Composto, medicamento, e, agentes preventivos ou remédios para asma e/ou bronquite, para rinite, para alergia , e para incontinência urinária
KR950703557A (ko) 약제로서 사용되는 헤테로아릴 화합물(Heteroaryl Compounds Used as Pharmaceuticals)
NO972938D0 (no) Farmasöytiske piperazinforbindelser

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: C07D 265/30, C07D 265/32, C07D 413/06, C07D 413/14, C07D 491/107, C07D 495/10,A61K 31/535, A61K 31/5353, A61K 31/55, A61P 11/00, A61P 11/06, A61P 13/00

Ipc: C07D 265/30 (2009.01), C07D 265/32 (2009.01), C07D

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements